Desjardins, A., Chandramohan, V., Herndon, J. E. I. I., Threatt, S., Bullock, C., Bradbury, C., … Bigner, D. D. (2024). CTIM-13. D2C7-IT IN COMBINATION WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM). In Neuro-Oncology (Vol. 26, pp. viii87–viii87). Oxford University Press (OUP). https://doi.org/10.1093/neuonc/noae165.0346

Desjardins, Annick, Vidya Chandramohan, James E. I. I. Herndon, Stevie Threatt, Chevelle Bullock, Claire Bradbury, Margaret O. Johnson, et al. “CTIM-13. D2C7-IT IN COMBINATION WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM).” In Neuro-Oncology, 26:viii87–viii87. Oxford University Press (OUP), 2024. https://doi.org/10.1093/neuonc/noae165.0346.

Desjardins A, Chandramohan V, Herndon JEII, Threatt S, Bullock C, Bradbury C, et al. CTIM-13. D2C7-IT IN COMBINATION WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM). In: Neuro-Oncology. Oxford University Press (OUP); 2024. p. viii87–viii87.

Desjardins, Annick, et al. “CTIM-13. D2C7-IT IN COMBINATION WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM).” Neuro-Oncology, vol. 26, no. Supplement_8, Oxford University Press (OUP), 2024, pp. viii87–viii87. Crossref, doi:10.1093/neuonc/noae165.0346.

Desjardins A, Chandramohan V, Herndon JEII, Threatt S, Bullock C, Bradbury C, Johnson MO, Khasraw M, Low JT, Peters KB, Shoaf M, Landi D, Batich K, Friedman AH, Friedman HS, Ashley DM, Knorr D, Osorio J, Ravetch J, Bigner DD. CTIM-13. D2C7-IT IN COMBINATION WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM). Neuro-Oncology. Oxford University Press (OUP); 2024. p. viii87–viii87.